Shares of Verrica Pharmaceuticals Inc. (VRCA) have gained nearly 30% year-to-date as this dermatology therapeutics company looks forward to the PDUFA date of its lead product candidate YCANTH, which is slated for June 23, 2021.
YCANTH, also known as VP-102, is a proprietary drug-device combination of Cantharidin administered through the company's single-use precision applicator. YCANTH is proposed for the treatment of molluscum contagiosum, a highly contagious viral skin disease that affects approximately six million people - primarily children - in the United States.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com